Literature DB >> 12871162

DNA topoisomerases as targets for antiprotozoal therapy.

R P Bakshi1, T A Shapiro.   

Abstract

Diseases caused by parasitic protozoa present a health problem of immense magnitude, and there is an urgent need for safe and effective new therapies. DNA topoisomerases are clinically relevant targets for anti-cancer and anti-bacterial agents. Inhibitor studies on parasite topoisomerases have revealed that these enzymes have great promise as molecular targets for anti-parasitics, and have helped to dissect the basic biology of DNA topoisomerases in these organisms. This review provides a brief introduction to DNA topoisomerases and anti-topoisomerase drugs, and an overview of studies on protozoal DNA topoisomerases and their inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871162     DOI: 10.2174/1389557033487863

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  12 in total

Review 1.  Antiparasitic compounds that target DNA.

Authors:  W David Wilson; Farial A Tanious; Amanda Mathis; Denise Tevis; James Edwin Hall; David W Boykin
Journal:  Biochimie       Date:  2008-03-04       Impact factor: 4.079

2.  Discovery of 2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one derivatives as possible antileishmanial agents.

Authors:  Anuradha Seth; Anirban Ghoshal; Varun Dewaker; Ankita Rani; Sangh Priya Singh; Mukul Dutta; Shivani Katiyar; Sandeep Kumar Singh; Mamunur Rashid; Muhammad Wahajuddin; Susanta Kar; Ajay Kumar Srivastava
Journal:  RSC Med Chem       Date:  2022-05-11

3.  Activity of indenoisoquinolines against African trypanosomes.

Authors:  Rahul P Bakshi; Dongpei Sang; Andrew Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

4.  Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation.

Authors:  Junya Kobayashi; Akihiro Kato; Yosuke Ota; Reiko Ohba; Kenshi Komatsu
Journal:  Mol Cancer       Date:  2010-02-09       Impact factor: 27.401

5.  T-2307 causes collapse of mitochondrial membrane potential in yeast.

Authors:  Tatsuya Shibata; Toshinari Takahashi; Eio Yamada; Akiko Kimura; Hiroshi Nishikawa; Hiroyoshi Hayakawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

6.  Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.

Authors:  Rafael Balaña-Fouce; Christopher F Prada; José María Requena; Mark Cushman; Yves Pommier; Raquel Álvarez-Velilla; José Miguel Escudero-Martínez; Estefania Calvo-Álvarez; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

Review 7.  Stability of Therapeutic Enzymes: Challenges and Recent Advances.

Authors:  Shubhrima Ghosh; Shahenvaz Alam; Anurag S Rathore; S K Khare
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

8.  Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum.

Authors:  Amit Roy; Ilda D'Annessa; Christine J F Nielsen; David Tordrup; Rune R Laursen; Birgitta Ruth Knudsen; Alessandro Desideri; Felicie Faucon Andersen
Journal:  Mol Biol Int       Date:  2011-05-04

9.  Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

Authors:  César Ordóñez; Javier Alfonso; Rafael Balaña-Fouce; David Ordóñez
Journal:  J Biomed Biotechnol       Date:  2009-07-27

10.  Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major.

Authors:  Rafael Balaña-Fouce; Carlos García-Estrada; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  BMC Microbiol       Date:  2008-07-08       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.